Interrupting herpes simplex virus type 2 transmission: The role of condoms and microbicides

Herpes

Volumn 11, Issue SUPPL. 3, 2004, Pages

  Langenberg, Andria ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Barrier; Condoms; Contraception; Developed world; Developing world; Genital herpes; HSV 2; Microbicides; Seroprevalence; STI; Transmission; Viruses

Indexed keywords

ACIDFORM; ADENINE DERIVATIVE; ANTIVIRUS AGENT; BETAINE DERIVATIVE; BUFFER; CARBOPOL 974P; CARRAGEENAN; DETERGENT; HERPES SIMPLEX VACCINE; LATEX; NAPHTHALENE DERIVATIVE; NONOXINOL 9; PHOSPHONYLMETHOXYPROPYLADENINE; POLYMER; POLYSTYRENESULFONIC ACID; PRO 2000 5; SAVVY; SURFACTANT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONDOM; CONFERENCE PAPER; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; NEWBORN INFECTION; PATIENT COUNSELING; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SAFE SEX; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION;

ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; CONDOMS; FEMALE; HERPES GENITALIS; HUMANS; MALE; NONOXYNOL; SEROEPIDEMIOLOGIC STUDIES;

HERPES; HUMAN HERPESVIRUS 2;

EID: 4344590393     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-3106.
2. Judson FN, Ehret JM, Bodin GF, Levin MJ, Rietmeijer CA. In vitro evaluations of condoms with and without nonoxynol 9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989;16:51-56.
3. Singh B, Posti B, Cutler JC. Virucidal effect of certain chemical contraceptives on Type 2 herpesvirus. Am J Obstet Gynecol 1976; 126:422-425.
4. Postic B, Singh B, Squeglia NL, Guevarra LO. Inactivation of clinical isolates of Herpesvirus hominis, types 1 and 2, by chemical contraceptives. Sex Transm Dis 1978;5:22-24.
5. Corey L. Herpes simplex virus. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th edn. (Mandell GL, Douglas RG, Bennett JE et al., eds). Philadelphia: Churchill Livingstone, 2000: pp1564-1580.
6. Casper C, Wald A. Condom use and the prevention of genital herpes acquisition. Herpes 2002;9:10-14.
7. Kish LS, McMahon JT, Bergfeld WF, Pelachyk JM. An ancient method and a modern scourge: the condom as a barrier against herpes. J Am Acad Dermatol 1983; 9:769-770.
8. McNiell ET, Gilmore CE, Finger WR, Lewis JH, Schellstede WP. The Latex Condom: Recent Advances, Future Directions. North Carolina: Family Health International, 1999.
9. Cates W, Jr, Stone KM. Family planning, sexually transmitted diseases and contraceptive choice: a literature update - Part I. Fam Plann Perspect 1992;24: 75-84.
10. Herman BA, Carey RF, Rinaldi JE. Sensitivity of water leak tests for latex condoms. J Test Eval 1993;21:124-128.
11. Conant MA, Spicer DW, Smith CD. Herpes simplex virus transmission: condom studies. Sex Transm Dis 1984;11:94-95.
12. Carey RF, Herman WA, Retta SM, Rinaldi JE, Herman BA, Athey TW. Effectiveness of latex condoms as a barrier to human immunodeficiency virus-sized particles under conditions of simulated use. Sex Transm Dis 1992;19: 230-234.
13. Lytle CD, Routson LB, Seaborn GB, Dixon LG, Bushar HF, Cyr WH. An in vitro evaluation of condoms as barriers to a small virus. Sex Transm Dis 1997:24: 161-164.
14. Trussell J, Warner DL, Hatcher R. Condom performance during vaginal intercourse: comparison of Trojan-Enz and Tactylon condoms. Contraception 1992;45:11-19.
15. HIV infection in European female sex workers: epidemiological link with use of petroleum-based lubricants. European Working Group on HIV Infection in Female Prostitutes. AIDS 1993;7:401-408.
16. Martin DJ. Inappropriate lubricant use with condoms by homosexual men. Public Health Rep 1992;107: 468-473.
17. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342:844-850.
18. Krone MR, Tabet SR, Paradise M, Wald A, Corey L, Celum CL. Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. J Infect Dis 1998;178:978-982.
19. O'Brien FP. Work-related fear of AIDS and social-desirability response bias. Psychol Rep 1989;65: 371-378.
20. Shlay JC, McClung MW, Patnaik JL, Douglas JM, Jr. Comparison of sexually transmitted disease prevalence by reported level of condom use among patients attending an urban sexually transmitted disease clinic. Sex Transm Dis 2004;31:161-162.
21. Austin H, Macaluso M, Nahmias A, Lee FK, Kelaghan J, Fleenor M et al. Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Sex Transm Dis 1999;26: 329-334.
22. Lowhagen GB, Tunback P. Andersson K, Johannisson G. Recurrent genital herpes in a population attending a clinic for sexually transmitted diseases. Acta Derm Venereol 2001;81:35-37.
23. Nahmias AJ, Lee FK, Beckman-Nahmias S. Seroepidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990;69: 19-36.
24. Wald A, Koutsky L, Ashley RL, Corey L. Genital herpes in a primary care clinic. Demographic and sexual correlates of herpes simplex type 2 infections. Sex Transm Dis 1997;24:149-155.
25. Huerta K, Berkelhamer S, Klein J, Ammerman S, Chang J, Prober CG. Epidemiology of herpes simplex virus type 2 infections in a high-risk adolescent population. J Adolesc Health 1996;18: 384-386.
26. Sucato G, Celum C, Dithmer D, Ashley R, Wald A. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. Pediatr Infect Dis J 2001;20:422-426.
27. Noell J, Rohde P, Ochs L, Yovanoff P, Alter MJ, Schmid S et al. Incidence and prevalence of chlamydia, herpes, and viral hepatitis in a homeless adolescent population. Sex Transm Dis 2001;28:4-10.
28. Butler T, Donovan B, Taylor J, Cunningham AL, Mindel A, Levy M et al. Herpes simplex virus type 2 in prisoners, New South Wales, Australia. Int J STD AIDS 2000;11: 743-747.
29. Gibney L, Saquib N, Macaluso M, Hasan KN, Aziz MM, Khan AY et al. STD in Bangladesh's trucking industry: prevalence and risk factors. Sex Transm Infect 2002;78:31-36.
30. Suligoi B, Tchamgmena O, Sarmati L, Bugarini R, Toma L, Bakary DK et al. Prevalence and risk factors for herpes simplex virus type 2 infection among adolescents and adults in northern Cameroon. Sex Transm Dis 2001;28:690-693.
31. Smith JS, Herrero R, Munoz N, Eluf-Neto J, Ngelangel C, Bosch FX et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis 2001;28: 187-194.
32. Rodriguez AC, Castle PE, Smith JS, Bratti C, Hildesheim A, Schiffman M et al. A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. Sex Transm Infect 2003;79:460-465.
33. Oberle MW, Rosero-Bixby L, Lee FK, Sanchez-Braverman M, Nahmias AJ, Guinan ME. Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. Am J Trop Med Hyg 1989;41:224-229.
34. Dobbins JG, Mastro TD, Nopkesorn T, Sangkharomya S, Limpakarnjanarat K, Weniger BG et al. Herpes in the time of AIDS: a comparison of the epidemiology of HIV-1 and HSV-2 in young men in northern Thailand. Sex Transm Dis 1999;26:67-74.
35. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993;167:942-946.
36. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
37. Xu F, Kilmarx PH, Supawitkul S, Manopaiboon C, Yanpaisarn S, Limpakarnjanarat K et al. Incidence of HIV-1 infection and effects of clinic-based counseling on HIV preventive behaviors among married women in northern Thailand. J Acquir Immune Defic Syndr 2002;29:284-288.
38. Pleck JH, Sonenstein FL, Ku L. Changes in adolescent males' use of and attitudes toward condoms, 1988-1991. Fam Plann Perspect 1993:25:106-110, 117.
39. Grady WR, Klepinger DH, Billy JO, Tanfer K. Condom characteristics: the perceptions and preferences of men in the United States. Fam Plann Perspect 1993;25: 67-73.
40. Whaley KJ, Barratt RA, Zeitlin L, Hoen TE, Cone RA. Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. J Infect Dis 1993;168: 1009-1011.
41. Moench TR, Whaley KJ, Mandrell TD, Bishop BD, Witt CJ, Cone RA. The cat/feline immunodeficiency virus model for transmucosal transmission of AIDS: nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 1993;7:797-802.
42. Cates W. Contraception, contraceptive technology, and STDs. In: Sexually Transmitted Diseases. (Holmes K, Sparling P, Mardh PA et al., eds). New York: McGraw Hill, 1999; pp1067-1078.
43. Phillips DM, Zacharopoulos VR. Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. Contraception 1998;57: 341-348.
44. Van Damme L. Advances in topical microbicides (Abstract P104). 13th International Conference on AIDS, Durban, South Africa, 2000.
45. Achilles S, Shete P, Moench T, Cone R. Evaluating acute in vivo toxicity of microbicides on genital tract epithelium. Int J STD AIDS 2001;12(Suppl 2):35.
46. Patton D, Cosgrove Sweeney Y, Rabe L, Hillier S. Effects of multiple applications of nonoxynol-9 on rectal tissues and microflora in a monkey model. Int J STD AIDS 2001;12(Suppl 2):35.
47. Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 2000;62: 149-154.
48. Norvell MK, Benrubi GI, Thompson RJ. Investigation of microtrauma after sexual intercourse. J Reprod Med 1984;29:269-271.
49. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001;184:418-428.
50. Zeitlin L, Whaley KJ. Microbicides for preventing transmission of genital herpes. Herpes 2002;9:4-9.
51. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001;28:417-423.
52. Bowcut J. Mapping Non-HIV Targets: What's in the Pipeline? Alliance for Microbicide Development, 17 March 2003; Abstract http://www.microbicide.org/ microbicideinfo/reference/Bowcut.mtg7.pdf. Last accessed 22 April 2004.
53. Cassone A, Boccanera M, Adriani D, Santoni G, De Bernardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995;63:2619-2624.
54. Peterson EM, Cheng X, Motin VL, de la Maza LM. Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect Immun 1997;65:2693-2699.
55. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990;64:3151-3156.
56. Zeitlin L, Whaley KJ, Sanna PP, Moench TR, Bastidas R, De Logu A et al. Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2. Virology 1996;225:213-215.
57. Zeitlin L, Castle PE, Whaley KJ, Moench TR, Cone RA. Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. J Reprod Immunol 1998;40:93-101.
58. Sherwood JK, Zeitlin L, Whaley KJ, Cone RA, Saltzman M. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat Biotechnol 1996;14: 468-471.
59. Franchetti P, Abu Sheikha G, Cappellacci L, Marchetti S, Grifantini M, Balestra E et al. A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. Antiviral Res 2000;47:149-158.